New application of bergamottin
By using bergamot as an antiviral drug, it inhibits Dabie Banda virus infection and reduces the number of virus copies in the kidney, spleen and lung tissues, solving the problem of lack of effective anti-Dibe Banda virus in the prior art, and achieving the The treatment and prevention effects of this virus infection and related diseases.
Patent Information
- Application Number
- CN202411004588.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
AI Technical Summary
In the prior art, there is a lack of effective anti-Dabé Banda virus substances, and it is difficult to effectively treat and prevent organ damage and fever and thrombocytopenia syndrome caused by the virus.
As a furancoumarin, bergamotin, reduces the number of virus copies in the kidney, spleen and lung tissues by inhibiting viral infection. It is used to prepare antiviral products and drugs for the treatment and prevention of Dabi Banda virus infection.
Bergamoto can effectively inhibit Dabi Banda virus infection and reduce the number of virus copies in the kidney, spleen and lung tissues. It has the effect of treating and preventing Dabi Banda virus infection and related diseases, and expanding the selection of antiviral substances.
Smart Images

Figure CN118903108A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of new drug applications, and in particular to new applications of bergamotin. Background Art
[0002] Dabie bandavirus (DBV) is a single-stranded negative-sense RNA virus belonging to the order Bunyavirales, family Leucoviridae, genus Bandavirus. Dabie bandavirus particles are generally spherical. Its genome consists of three segmented RNA segments: the L segment encodes RdRP, the M segment encodes glycoproteins Gn and Gc, and the S segment encodes nucleoprotein N and non-structural protein NS.
[0003] DBV is mainly transmitted through the bites of vectors such as infected long-horned ticks. It can also cause infection through unprotected contact with the blood, secretions, excretions and contaminants of infected animals or patients. DBV directly acts on multiple cells in the human body and causes tissue and organ damage. The virus attacks the human lymph nodes, causing lymphadenopathy and necrotizing lymphadenitis. After rapid replication in the lymph nodes and spleen, it enters the systemic circulation, forming viremia and attacking multiple tissues and organs at the same time. Among them, fever with thrombocytopenia syndrome is an acute infectious disease caused by Dabie bandavirus (DBV; formerly known as severe fever with thrombocytopenia syndrome virus, SFTSV). SFTSV infects the body and causes immune dysfunction. In severe cases, it can induce cytokine storms and endothelial damage. Patients may die from bleeding or multiple organ failure.
[0004] Although some natural extracts in the prior art have certain therapeutic effects on Dabie Banda virus and the organ damage or fever with thrombocytopenia syndrome caused by it, there are still a large number of natural extracts that have not been found to have anti-Dabie Banda virus effects, and it is necessary to further expand the selection of anti-Dabie Banda virus substances.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The purpose of the present invention is to provide a new application of bergamot. The bergamot provided by the embodiment of the present invention can effectively inhibit the infection of Dabie Banda virus, and can reduce the number of viral copies in kidney, spleen and lung tissues. Then, bergamot can be used to treat and / or prevent Dabie Banda virus infection, and has a certain therapeutic effect on organ damage and / or fever with thrombocytopenia syndrome caused by its infection, further expanding the selection of anti-Dabie Banda virus substances.
[0007] The present invention is achieved in that:
[0008] In a first aspect, the present invention provides a use of bergamot in the preparation of an antiviral preparation for treating and / or preventing bunyavirus infection.
[0009] In an alternative embodiment, the Bunyavirus comprises Bebanda virus.
[0010] In a second aspect, the present invention provides a use of bergamotin in the preparation of an antiviral preparation for treating and / or preventing Dabiebandha virus infection.
[0011] In an optional embodiment, the antiviral preparation includes antiviral drugs and / or antiviral functional foods.
[0012] In an alternative embodiment, the antiviral preparation is a preparation that reduces viral titer.
[0013] In an alternative embodiment, the antiviral preparation is a preparation that reduces the number of viral RNA copies in kidney, spleen and / or lung tissue.
[0014] In an optional embodiment, the antiviral preparation further comprises an auxiliary material.
[0015] In a third aspect, the present invention provides a use of bergamotin as the sole active ingredient in the preparation of an antiviral drug for treating and / or preventing Dabiebandha virus infection.
[0016] In a fourth aspect, the present invention provides a use of bergamot in the preparation of a medicament for treating fever with thrombocytopenia syndrome.
[0017] In a fifth aspect, the present invention provides a use of bergamotin in the preparation of a medicament for treating tissue and / or organ damage caused by Bandar Virus.
[0018] The present invention has the following beneficial effects: the bergamot provided by the embodiment of the present invention can effectively inhibit the infection of the Dabie Banda virus, and can reduce the number of viral copies in the kidney, spleen and lung tissues. Then, the bergamot can be used to treat and / or prevent the Dabie Banda virus infection, and has a certain therapeutic effect on the organ damage and / or fever with thrombocytopenia syndrome caused by the infection, which further expands the selection of substances against the Dabie Banda virus and further expands the application of the bergamot. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0020] Figure 1 This is a result diagram of the effect of bergamot extract on inhibiting DBV provided in Experimental Example 1 of the present invention;
[0021] Figure 2 The result diagram of the cytotoxicity of bergamotrin provided in Experimental Example 2 of the present invention;
[0022] Figure 3 The result graph of the bergamot extract inhibiting the viral RNA copy number in the kidney of DBV-infected immunodeficient mice provided in Experimental Example 3 of the present invention;
[0023] Figure 4 This is a result diagram of the bergamot extract provided in Experimental Example 3 of the present invention inhibiting the viral RNA copy number in the spleen of DBV-infected immunodeficient mice;
[0024] Figure 5 This is a result diagram of the bergamot extract provided in Experimental Example 3 of the present invention inhibiting the number of viral RNA copies in the lungs of immunodeficient mice infected with DBV;
[0025] Figure 6 This is a result diagram of the bergamot extract provided in Experimental Example 3 of the present invention inhibiting the viral RNA copy number in the liver of DBV-infected immunodeficient mice;
[0026] Figure 7 and Figure 8 This is a graph showing the effect of bergamot extract on Nipah virus infection in cells provided in Experimental Example 4 of the present invention. DETAILED DESCRIPTION
[0027] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0028] Bergamot is named Citrus bergamia, a plant belonging to the genus Citrus in the Rutaceae family. The structural formula of bergamotin is shown below:
[0029]
[0030] Bergamottin is a furanocoumarin, named after the oil of bergamot in which it was originally discovered. It is also a biologically active component of grapefruit and other citrus fruits. Bergamottin is an inhibitor of cytochrome P450 (CYP) enzymes. It can also inhibit the activity of CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4 in human liver microsomes. In general, furanocoumarins can exhibit a variety of pharmacological properties, including antioxidant, anti-inflammatory and anticancer activities. Bergamottin has shown significant anticancer activity in skin, myeloma, leukemia, lung cancer and other cancer cells, but there is no record of its effect on the Bandar virus.
[0031] The inventors have made creative efforts to discover that bergamotin can be used to treat and / or prevent Dabiebandha virus infection. Specifically, it can be used to prepare antiviral products for treating and / or preventing Dabiebandha virus infection. The antiviral product can be an antiviral drug, or an antiviral functional food, such as a health product. In addition to the active ingredient bergamotin, the above-mentioned product can also include a pharmaceutical excipient, which is an existing known excipient that does not affect the efficacy of bergamotin, and the antiviral drug is a medicament prepared by mixing the pharmaceutical excipient with bergamotin, or it can be a drug package in which the pharmaceutical excipient and bergamotin are stored separately and taken at the same time.
[0032] In the embodiments of the present invention, bergamot can be the only active ingredient in the antiviral drug. However, it is understandable that bergamot can also be combined with other antiviral drugs or other active drugs that do not affect the antiviral efficacy of bergamot to treat the corresponding disease or inhibit the corresponding virus.
[0033] Specifically, in the embodiments of the present invention, bergamotin can reduce the number of viral RNA copies, specifically reduce the viral titer in the kidney, spleen and / or lung tissues, and then can treat and / or prevent Dabiebandha virus infection, and also has a certain therapeutic effect on related diseases caused by Dabiebandha virus infection.
[0034] The features and performances of the present invention are further described in detail below in conjunction with experimental examples.
[0035] Experimental Example 1
[0036] Experiment on the inhibition of DBV infection by bergamot
[0037] Methods: VeroE6 cells were treated with bergamot at concentrations of 50μM, 25μM, 12.5μM, 6.25μM, 3.125μM, 1.5625μM, 0.78125μM and 0.390625μM for 1 hour. In the presence of drugs, DBV was infected with MOI=0.01 for 2 hours, and the mixture of drugs and viruses was discarded, and the medium was replaced with the corresponding concentration of drug-containing medium for 48 hours. The cells in the wells were rinsed with 4% paraformaldehyde to terminate the infection, and the DBV nucleoprotein antibody was used as a specific antibody to label the virus, and the infection of the virus in the cells was detected by immunofluorescence.
[0038] Results Figure 1 ,according to Figure 1 It can be seen that bergamot can effectively inhibit DBV infection, and inhibit DBV infection in a dose-dependent manner within the non-toxic range. 50 The half-maximal inhibitory concentration (50%, calculated by nonlinear fitting using Graphpad Prism 8.0 software) was 8.555 μM.
[0039] Experimental Example 2
[0040] Bergamot cytotoxicity test
[0041] Methods: CCK 8 kit was used to determine the cytotoxicity of drugs. WST 8 (2(2-methoxy-4-nitrophenyl)3(4-nitrophenyl)5(2,4-disulfonylbenzene)2H tetrazolium monosodium salt) in the kit can be reduced to highly water-soluble orange-yellow formazan by some dehydrogenases in mitochondria under the action of electron coupling carrier 1Methoxy PMS. The color depth of the generated formazan is proportional to the cell activity and inversely proportional to the cytotoxicity. After the drugs with different concentration gradients were co-incubated with cells for a corresponding period of time, the absorbance value was measured at a wavelength of 450nm using an enzyme marker, which can indirectly reflect the number of living cells. Among them, the set concentrations of bergamotin were 500μM, 250μM, 125μM, 62.5μM, 31.25μM, 15.625μM, 7.8125μM, 3.90625μM, 1.953125μM and 0.9765625μM, respectively.
[0042] Results Figure 2 ,according to Figure 2 It can be seen that there is no obvious cytotoxicity at a concentration of 100 μM, indicating that bergamotin is a safe and effective drug against Dabiebandha virus infection.
[0043] Experimental Example 3
[0044] Therapeutic effect of bergamotin on immunodeficient mice infected with DBV
[0045] Methods: Immunodeficient mice were used as infection models, and the experiment was divided into virus group and treatment group. Immunodeficient mice in the treatment group were gavaged with bergamot 1 hour before infection, and the immunodeficient mice were infected with the virus by intraperitoneal injection of 10LD50 DBV. After infection, the immunodeficient mice in the treatment group were gavaged with bergamot once a day, with a dosage of 75mg / kg and 120mg / kg; the immunodeficient mice in the virus group were gavaged with solvent (corn oil) 1 hour before infection, and the immunodeficient mice were infected with the virus by intraperitoneal injection of 10LD50 DBV. After infection, the immunodeficient mice in the virus group were gavaged with solvent once a day, and the dosage was consistent with that of the treatment group. The drug was continuously administered and observed until the fourth day after infection.
[0046] Results Figures 3 to 6 .in, Figure 3 The graph shows the results of bergamot inhibiting the viral RNA copy number in the kidney of DBV-infected immunodeficient mice; Figure 4 The graph shows the results of bergamot inhibiting the viral RNA copy number in the spleen of DBV-infected immunodeficient mice; Figure 5 The results of the graph showing that bergamotin inhibits the number of viral RNA copies in the lungs of DBV-infected immunodeficient mice; Figure 6 The graph shows the results of bergamotin inhibiting the viral RNA copy number in the liver of DBV-infected immunodeficient mice.
[0047] according to Figures 3 to 6 It can be seen that different doses of bergamot can significantly reduce the RNA copy number of DBV in the kidney, spleen and lung tissues of infected immunodeficient mice, but no significant decrease was observed in the viral RNA copy number in the liver. It can be seen that bergamot specifically reduces the RNA copy number of DBV in the kidney, spleen and lung tissues.
[0048] Experimental Example 4
[0049] Effect of bergamotin on Nipah pseudotype virus infection experiment
[0050] Methods: NiV is a virulent RNA virus originating from bats, belonging to the genus Henipavirus of the family Paramyxoviridae. By transfecting plasmids carrying the vesicular stomatitis virus (VSV) gene and plasmids containing Nipah Virus envelope glycoproteins (G protein and F protein), recombinant viruses with Nipah virus envelope glycoproteins and reporter genes were constructed. While simulating the virus infection process, high-throughput screening and detection can be carried out conveniently and timely. Vero cells were incubated with bergamotrin at concentrations of 100μM, 50μM, 25μM, 12.5μM, 6.25μM, 3.125μM and 1.5625μM for 1 hour. In the presence of drugs, NiVpv infected cells for 1 hour, then the mixture of drugs and viruses was discarded, and the medium was replaced with the corresponding concentration of drug-containing culture medium for 24 hours. After 24 hours, the infection of the virus in the cells was reflected by lysing the cells to detect the activity value of Renilla luciferase. Results are shown in Figure 7 .
[0051] The same method was used, and the concentrations of bergamotin used were 120 μM, 40 μM, 13 μM, 4 μM, 1.5 μM, 0.5 μM, 0.16 μM, 0.05 μM and 0.390625 μM. The results are shown in Figure 8 .
[0052] according to Figure 7 and 8 It can be seen that bergamot extract cannot effectively inhibit NiVpv infection, and there is no drug dose-dependent inhibition.
[0053] In conclusion, bergamotin inhibited DBV infection in a dose-dependent manner within the non-toxic range. 50 It is 8.555 μM, and there is no obvious cytotoxicity at the action concentration of 100 μM, indicating that bergamotin is a safe and effective drug against Dabiebandha virus infection.
[0054] The antiviral effect of the drug was evaluated using an immunodeficient mouse model. The experimental results confirmed that after infected immunodeficient mice were treated with 75 mg / kg of bergamot daily by gavage, the number of DBV virus copies in the kidney, spleen and lung tissues was significantly lower than that in the control group, indicating that bergamot can prevent and / or treat Dabiebandha virus infection.
[0055] Combined with the Nipah pseudotype virus infection experiment, it further demonstrated that bergamot can specifically target Dabiebandha virus infection, and not all viruses can be inhibited by bergamot.
[0056] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of bergamot in the preparation of an antiviral product for treating and / or preventing bunyavirus infection.
2. The use according to claim 1, characterized in that: The bunyaviruses include the Bebanda virus.
3. Use of bergamot in the preparation of an antiviral product for treating and / or preventing Dabiebandha virus infection.
4. The use according to claim 3, characterized in that: The antiviral products include antiviral drugs and / or antiviral functional foods.
5. The use according to claim 3, characterized in that: The antiviral preparation is a preparation that reduces virus titer.
6. The use according to claim 3, characterized in that: The antiviral preparation is a preparation that reduces the number of viral RNA copies in kidney, spleen and / or lung tissues.
7. The use according to claim 3, characterized in that: The antiviral preparation also includes auxiliary materials.
8. Use of bergamotin as the sole active ingredient in the preparation of an antiviral drug for treating and / or preventing Dabiebandha virus infection.
9. Use of bergamot in the preparation of a drug for treating fever with thrombocytopenia syndrome.
10. Use of bergamot in the preparation of a drug for treating tissue and / or organ damage caused by Dabiebandha virus.
